Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = shorter BEAT-TB India regimen

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
10 pages, 409 KB  
Brief Report
The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB
by Malaisamy Muniyandi, Paranchi Murugesan Ramesh, William A. Wells, Umesh Alavadi, Suvanand Sahu and Chandrasekaran Padmapriyadarsini
Trop. Med. Infect. Dis. 2023, 8(8), 411; https://doi.org/10.3390/tropicalmed8080411 - 11 Aug 2023
Cited by 4 | Viewed by 3076
Abstract
Objective: To measure the economic impacts of the longer pre-XDR-TB treatment regimen and the shorter BEAT-TB India regimen. Methods: In the current study, the economic impacts of the current 18-month pre-XDR-TB treatment regimen and the 6–9 month BEAT-TB regimen were evaluated using an [...] Read more.
Objective: To measure the economic impacts of the longer pre-XDR-TB treatment regimen and the shorter BEAT-TB India regimen. Methods: In the current study, the economic impacts of the current 18-month pre-XDR-TB treatment regimen and the 6–9 month BEAT-TB regimen were evaluated using an economic model via a decision tree analysis from a societal perspective. The incremental costs and quality-adjusted life years (QALYs) gained from the introduction of the BEAT-TB regimen for pre-XDR-TB patients were estimated. Results: For a cohort of 1000 pre-XDR-TB patients, we found that the BEAT-TB India regimen yielded higher undiscounted life years (40,548 vs. 21,009) and more QALYs gained (27,633 vs. 15,812) than the 18-month regimen. The BEAT-TB India regimen was found to be cost-saving, with an incremental cost of USD −128,651 when compared to the 18-month regimen. The current analysis did not consider the possibility of reduced TB recurrence after use of the BEAT-TB regimen, so it might have under-estimated the benefits. Conclusion: As a lower-cost intervention with improved health outcomes, the BEAT-TB India regimen is dominant when compared to the 18-month regimen. Full article
Show Figures

Figure 1

Back to TopTop